AlphAIalphai — Financial news for AI agents
GlobeNewswireAPR 104 min read$ALLO

Allogene Therapeutics to Announce Interim Futility Analysis Data from its Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation LBCL on Monday, April 13, 2026

Allogene Therapeutics, Inc. announced it will host a conference call and webcast on Monday, April 13, 2026, to review interim futility analysis data from its pivotal Phase 2 ALPHA3 trial. This trial evaluates cemacabtagene ansegedleucel (cema-cel) in first-line consolidation large B-cell lymphoma (LBCL). The company, a clinical-stage biotechnology firm, specializes in developing allogeneic CAR T products for cancer and autoimmune diseases.

Original reporting
GlobeNewswire
Published Apr 10, 2026, 9:40 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Apr 10, 2026, 10:00 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Allogene Therapeutics to Announce Interim Futility Analysis Data from its Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation LBCL on Monday, April 13, 2026 — source image
Source · GlobeNewswire
Decision brief

The 30-second read

$ALLONeutralMed
01

Why it matters

Positive data could accelerate clinical adoption and stock appreciation; negative data may cause declines.

02

Market read

The trial results are highly relevant for investors in biotech and oncology sectors, potentially affecting stock prices and sector sentiment.

03

What to watch

Market reaction may be muted if results are inconclusive; broader biotech market trends could overshadow company-specific news.

Timing: high (scheduled announcement on April 13, 2026)

Background

Allogene Therapeutics is developing allogeneic CAR T therapies for cancer treatment, with Cema-Cel being a leading candidate.

Company-level read

Ticker impact

$ALLONeutralMedium confidence
Context

The news pertains directly to Allogene Therapeutics' clinical trial results, which could influence its stock price.

Expected impact

Potential short-term volatility; possible slight decline if interim results are unfavorable, or upward movement if positive.

Evidence & confidence

The trial results are pivotal but early data may not fully determine the stock's trajectory; market reaction depends on the actual data disclosed.

Market effects

Sector

Potential influence on biotech sector valuations, especially CAR T-cell therapies.

Regional

Limited regional impact; primarily relevant to US biotech markets.

Global

Moderate; as a clinical trial outcome, it could influence global biotech investor sentiment.

Counterpoint

What could challenge this read

Negative interim results could lead to a sharp decline in ALLO stock, presenting a shorting opportunity.

Key entities

  • Company
    Allogene Therapeutics, Inc.

    A biotech firm specializing in allogeneic CAR T-cell therapies.

  • Product
    Cemacabtagene Ansegedleucel (Cema-Cel)

    An investigational CAR T-cell therapy for LBCL.

Read at source← All news

Related articles

AUG 19
$ALLOMedAI 8/10

Allogene (ALLO) Q2 2026 Earnings Call Transcript

Allogene (ALLO) reported a Q2 2026 net loss of $42.7M, or $0.13 per share, with $4.6M in collaboration revenue. Cash reserves totaled $423.6M, providing a runway into 2029. Key clinical updates include 58.3% MRD negativity in the ALPHA3 trial and a 31% ORR for ALLO-316. The company aims to expand access to CAR T therapies in community settings. FDA granted RMAT and Fast Track designations for cema-cel. Management highlighted upcoming milestones and risks, including small data sets and safety cha

fool.com2 min
AUG 13
$ALLOMed

Allogene Therapeutics' Q2 Earnings Beat Estimates on Lower R&D Costs

Allogene Therapeutics (ALLO) reported Q2 2026 EPS loss of 13 cents, narrower than the Zacks Consensus loss of 16 cents, helped by lower R&D costs. Collaboration revenue from related parties was $4.6 million. Cash, cash equivalents and investments rose to $423.6 million after a $200.4 million April offering. The company reiterated 2026 operating expense guidance and expects ALPHA3 interim EFS data in mid-2027.

tradingview.com6 min
AUG 12
$ALLOMed

Allogene Therapeutics, Inc. (ALLO): Results of Operations and Financial Condition

Allogene Therapeutics, Inc. (ALLO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Allogene Therapeutics Reports Second Quarter 2026 Financial Results and Business Update • Pivotal Phase 2 ALPHA3 Program in 1L Large B-cell Lymphoma (LBCL): ◦ Recent Interim Futility Analysis Supports Cemacabtagene Ansegedleucel’s (Cema-Cel) Potential as an Outpatien

SEC EDGAR 8-K6 min
SEP 2
$BAHLowAI 8/10

Defeated by physics

In 2025, President Trump ordered the development of Golden Dome, a missile defense system with space-based interceptors. The Pentagon awarded $3.2B to 12 companies, including Booz Allen, to develop boost-phase defenses. Booz Allen proposed 'Brilliant Swarms,' a system of 2,000 small interceptor-satellites costing $25B to deploy. The system aims to intercept missiles before they release warheads and decoys, addressing threats from Russia and China. Critics argue such systems are costly and may no

thebulletin.org2 min
SEP 2
High

BofA downgrades Amrize to underperform, cuts price target on slower growth outlook

Bank of America downgraded Amrize to Underperform, cutting its price target to $40 from $50 due to slower earnings growth, market risks, and valuation concerns. The brokerage lowered its 2027-28 adjusted EBITDA and EPS estimates, citing stable U.S. cement prices, Canadian demand pressure from U.S. tariffs, and vulnerable roofing margins. BofA forecasts adjusted EBITDA growth of 3% and adjusted EPS growth of 6% annually over 2026-28, excluding large acquisitions. The bank also trimmed its buildin

investing.com2 min